Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 09-13-2012, 01:30 AM #1
NewsBot NewsBot is offline
News Gatherer
Community Support Team
 
Join Date: Dec 2007
Posts: 65,355
15 yr Member
NewsBot NewsBot is offline
News Gatherer
Community Support Team
 
Join Date: Dec 2007
Posts: 65,355
15 yr Member
Default Sanofi multiple sclerosis pill gets U.S. approval (Yahoo)

(Reuters) - French drugmaker Sanofi SA gained U.S. approval for its multiple sclerosis pill, Aubagio, on Wednesday -- one of the two MS treatments it is relying on to return to growth after several blockbuster drugs lost patent protection. The drug has milder side effects than rival MS drugs and analysts say it could find favor among newly diagnosed patients. Around 35 percent to 40 percent of MS patients prefer to take no medication rather than face unwanted side effects. ...




Read the full article...

(From Yahoo Diseases)
NewsBot is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
ANNagain (09-13-2012), Erika (09-13-2012), Jappy (09-14-2012), KittyLady (09-13-2012), SallyC (09-13-2012)
 


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off


Similar Threads
Thread Thread Starter Forum Replies Last Post
Experimental Pill for Multiple Sclerosis Shows Promise (Yahoo) NewsBot Multiple Sclerosis 1 04-17-2012 10:50 AM


All times are GMT -5. The time now is 03:43 PM.


Powered by vBulletin • Copyright ©2000 - 2025, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise (Lite) - vBulletin Mods & Addons Copyright © 2025 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.


Always consult your doctor before trying anything you read here.